Early Detection of Colorectal Cancer Made Easy with a Blood Test
|
|
- Roderick Fox
- 7 years ago
- Views:
Transcription
1 INFORMATION FOR PHYSICIANS Early Detection of Colorectal Cancer Made Easy with a Blood Test Epi pro Colon 2.0 : 2 nd Generation Septin 9 Test
2 CRC SCREENING SAVES LIVES Colorectal cancer is a major health problem in the industrialized world. More than 148,000 people in Europe and about 50,000 in the U. S. die of the disease every year, making colorectal cancer the second most common cause of cancer-related deaths (Figure 1). 1, 2 Death from colorectal cancer vs. traffic accidents 27,000 deaths from colorectal cancer < 4,000 deaths by traffic accidents Figure 1: Deaths from colorectal cancer and deaths by car accidents in Germany. Source: Felix Burda Foundation, 2009 Colorectal cancer is curable if diagnosed early Early detection can save the lives of people suffering from colorectal cancer. Most cases of colorectal cancer (CRC) are curable if diagnosed early enough. However, the chances of survival decrease, when the disease is diagnosed in more progressed stages (Figure 2) Survival Rate [%] Stage I Stage II Stage III Stage IV Figure 2: Survival rate for colorectal cancer by stage. Source: National Cancer Institute, PDQ, Treatment, Health Professionals Years
3 Colorectal cancer screening There is a variety of alternative procedures for CRC screening that may be divided into invasive and non-invasive methods. Established invasive methods comprise colonoscopic and sigmoidoscopic examination, while conventional methods include fecal occult blood testing (FOBT) by either guaiac-based (gfobt) or immunochemical-based stool tests (fecal immunochemical test, FIT) detection. All CRC screening methods have been proven to be effective in the battle against colorectal cancer. However, the majority of patients avoid such examinations, thus depriving themselves of the chance of early detection and a potential cure. Compliance to CRC screening a blood test makes the difference Despite numerous educational and informational campaigns, colorectal cancer screening is still not well-accepted: less than half of all eligible individuals participate in colorectal cancer screening today. A nationwide telephone survey in the United States with 1,304 participants aged 50 + conducted for Colorectal Cancer Alliance demonstrated that 75 % of the participants would get regular screening if a blood-based CRC screening assay was available. 3 In France 86 % of patients would agree to do regular screening with the blood test. 4 For these people the Septin 9 blood test is a viable alternative. THE SEPTIN 9 BLOOD TESTS: Early detection of colorectal cancer in the blood With Septin 9 blood tests, such as Epi pro Colon 2.0 CE, you can offer your patients a simple and safe alternative for early detection of colorectal cancer. The test detects the epigenetic biomarker Septin 9 in blood plasma. This biomarker methylated DNA of the Septin 9 gene correlates strongly with the presence of colorectal cancer. As the Septin 9 blood tests can be performed at any time and without discomfort to the patient, it offers considerable potential for increased patient acceptance and a real opportunity to lower the mortality rate from colorectal cancer. IMPORTANT FOR YOUR PATIENTS: The Septin 9 blood tests can be performed at any time and can easily be included in a general health checkup. No dietary restrictions are required before performing the test. Both blood sampling and discussion of test result are handeled in the physician s office with an average time for testing of around one week.
4 Study data Epi pro Colon 2.0 CE is a 2 nd generation Septin 9 blood test with substantially increased clinical performance compared to the first generation test. Performance evaluation studies demonstrated > 80 % sensitivity to colorectal cancer with 99 % specificity (Figure 3). The effectiveness of the Septin 9 blood test was determined in numerous studies involving thousands of participants including a prospective evaluation in a screening cohort of 8,000 subjects. 5 7 The first generation Septin 9 blood test, Epi pro Colon, has been available as a CE-marked kit since Oct 2009 in Europe. The Septin 9 blood test therefore offers a well established, safe and patient-friendly option of taking part in colorectal cancer screening that so often saves lives. # Samples 1/149 79/98 18/27 25/29 27/31 9/ % 99 % 81% 67 % 86 % 87 % 82 % 80 % Positivity 60 % 40 % 20 % 0 % CVNs * All CRC ** Stage I Stage II Stage III Stage IV * Colonoscopy verified normals ** Colorectal cancer Figure 3: Detection rates of the Epi procolon 2.0 CE blood-based 2 nd generation Septin 9 blood test by stage from three case-control studies. Comparison of Epi pro Colon 2.0 CE with non-invasive screening tests The most widely used non-invasive CRC screening methods are the guaiac FOBT and variations of the OC-Sensa Micro Test, an immunological FOBT. Compared to those methods the Epi pro Colon 2.0 CE has an unmatched positive predictive value at an equally high negative predictive value. On average one out of two positive tested patients has cancer and the probability of a true negative result is 99.9 %. Epi pro Colon 2.0 CE provides the most accurate option for non-invasive CRC screening combined with the unprecedented convenience of a blood test.
5 METHOD SPECIFICITY SENSITIVITY NEGATIVE PREDICTIVE VALUE POSITIVE PREDICTIVE VALUE 2 nd Generation Septin 9 Test Epi pro Colon % 80.6 % 99.9 % 45.7 % Guiac Fecal-Occult Blood Test % 37.1 % 99.6 % 10.1 % OC-Sensa Micro qfit1x % 69.2 % 99.8 % 7.5 % OC-Sensa Micro qfit3x % 84.6 % 99.9 % 5.6 % CRC with positive test result, healthy with positive test result assuming a prevalence for CRC of 0.7 % Septin 9 performance in polyps Normal epithelium Large adenoma Colon carcinoma SEPTIN 9 POSITIVE FRACTION 10 HEALTHY ADVANCED ADENOMA CANCER Tissue 8 % 100 % 100 % Plasma 15 % 35 % 75 % Figure 4: Detection rates of Septin 9 in plasma from patients suffering from advanced adenomas and cancer. Tissue samples from both adenomas and cancer were 100 % positive. The data were generated by Tóth et al. 10 with a modifi ed Epi procolon 1.0 assay.
6 Simple performance in the medical practice The Septin 9 blood test allows you to offer your patients a new, reliable alternative for early detection of colorectal cancer. No intestinal preparation is required before performing the test. There are no restrictions with regard to food or drug intake. The patient can be tested at any time by a simple blood draw which can easily be included in a general health checkup. Sampling for the test and communication and explaination of the test result is in the hand of the physician (Figure 5). Patient with average risk of colorectal cancer Blood sample Laboratory Test report Physician Figure 5: Schematic of Septin 9 clinical work-up Blood sampling for the test In order to perform the Epi pro Colon 2.0 CE blood test, a blood sample is taken using a 9.5 ml EDTA tube or a 8.5 ml CPDA tube and sent to a diagnostic laboratory which measures and evaluates Septin 9. Within approximately one week the test result is returned to the physician. Who should take the test? The test is suitable for everyone with an average risk of colorectal cancer, who has no symptoms, but wants to take part in colorectal cancer screening. The purpose of the test is not to replace screening colonoscopy. Instead, it is aimed at people looking for a safe alternative that enables them to take part in colorectal cancer screening. Test costs The Septin 9 blood test is a diagnostic method that, at present, may not or only partially be reimbursed in your country. Thus, the patient may have to bear all or part of the test costs. Please contact your local laboratory for the exact price. For a list of laboratories, which perform the test, please contact Epigenomics.
7 1. Lofton-Day et al, DNA-Methylation Biomarkers for Blood-Based Colorectal Cancer Screening, Clin. Chem, 2008;54: Grützmann et al, Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay, PLOS One, 2008;3(11):e DeVos T. et al, Circulation methylated SEPT9 DNA in Plasma as a Biomarker for Colorectal Cancer, Clin. Chem, 2009;55:7m Weiss G. and T. Rösch, Potenital of a new blood Test for Colorectal Cancer Screening-the Septin9 Gene Biomarker, European Oncology, Volume 6, Issue 1, (2010) 5. Church et al, Prospective clinical validation of an assay for methylated Septin 9 DNA in human plasma as a colorectal cancer screening tool in average risk men and women 50 years and older, Oral Presentation at DDW, Chicago, IL, m S9 real-time PCR Assay, Gebrauchsanleitung, Abbott Molecular, Rösch et al, Prospective Clinical Validation of a Biomarker, Methylated SEPT 9 DNA, for Colorectal Cancer Detection in Plasma of Average Risk Men and Women Over the Age of 50, Poster Presentation at UEGW, Barcelona, Spain, Heichmann et al, Use of Septin 9 Methylated DNA Biomarker to Detect Cancer in the Blood of Colorectal Cancer Patients Poster Presentation at ASCO-NCI-EORTC Annual Meeting on Molecular Markers, Hollywood, FL, Lofton-Day et al, DNA-Methylation Biomarkers for Blood-Based Colorectal Cancer Screening, Clin. Chem, 2008;54: Grützmann et al, Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay, PLOS One, 2008;3(11):e DeVos T. et al, Circulation methylated SEPT9 DNA in Plasma as a Biomarker for Colorectal Cancer, Clin. Chem, 2009;55:7m Weiss G. and T. Rösch, Potenital of a new blood Test for Colorectal Cancer Screening-the Septin9 Gene Biomarker, European Oncology, Volume 6, Issue 1, (2010) 5. Church et al, Prospective clinical validation of an assay for methylated Septin 9 DNA in human plasma as a colorectal cancer screening tool in average risk men and women 50 years and older, Oral Presentation at DDW, Chicago, IL, m S9 real-time PCR Assay, Gebrauchsanleitung, Abbott Molecular, Rösch et al, Prospective Clinical Validation of a Biomarker, Methylated SEPT 9 DNA, for Colorectal Cancer Detection in Plasma of Average Risk Men and Women Over the Age of 50, Poster Presentation at UEGW, Barcelona, Spain, Heichmann et al, Use of Septin 9 Methylated DNA Biomarker to Detect Cancer in the Blood of Colorectal Cancer Patients Poster Presentation at ASCO-NCI-EORTC Annual Meeting on Molecular Markers, Hollywood, FL, 2010 The test result The Septin 9 blood test result is either negative or positive with respect to the presence of Septin 9 in plasma (Figure 6). A negative test result means that the likelihood of the patient having colorectal cancer is extremely low. For Epi pro Colon 2.0 CE a negative test result indicates a probability of 99.9 % that the patient does not suffer from colorectal cancer (99.9 % negative predictive value). Nevertheless, as colorectal cancer can develop spontaneously over time, the patient should be advised to repeat the test every one or two years similar to conventional stool tests. A positive Septin 9 blood test result means that the likelihood of the patient having colorectal cancer is increased. For Epi pro Colon 2.0 CE a positive test results indicates a probability of 45 % that the patient suffers from cancer (45 % positive predictive value). These patients are strongly advised to undergo colonoscopy for establishing the diagnosis and initialization of treatment. Septin9 Test Result Analysis Report: Septin9 Test Result TEST RESULT: NEGATIVE Test Description: The Septin9 test Epi procolon detects presence of methylated Septin9 DNA ( m SEPT9) in a plasma sample of a patient. Test Methods: DNA purification from plasma, bisulfate conversion, duplex real-time PCR. Test Result: The blood plasma sample no. was analysed with the Septin9-Test Epi procolon. The analysis was done in replicate. A sample is classified as positive, when at least one of the two measurements was tests positive for m SEPT9. The sample submitted for analysis was classified as: Negative Analysis Report: Test Description: The Septin9 test Epi procolon detects presence of methylated Septin9 DNA ( m SEPT9) in a plasma sample of a patient. Test Methods: DNA purification from plasma, bisulfate conversion, duplex real-time PCR. Test Result: The blood plasma sample no. was analysed with the Septin9-Test Epi procolon. The analysis was done in replicate. A sample is classified as positive, when at least one of the two measurements was tests positive for m SEPT9. The sample submitted for analysis was classified as: Epi procolon 2.0 CE negative patients are correctly classified as healthy with 99.9 % probability. Screening should be done regularly. for the presence of m SEPT9 in blood plasma. Positive Test Analysis: It has been validated in several clinical studies that there is a strong association between detection of m SEPT9 in blood plasma with presence of colorectal cancer. for the presence of m SEPT9 in blood plasma. Comment on positive test result: a positive test result means that there is an increased likelihood for the presence of CRC. Individuals with positive test results are encouraged to undergo a diagnostic colonoscopy. From 20 positive tests, an average of 1 person will be diagnosed with Test Analysis: It has been validated in several clinical studies that there is a strong association CRC and 7 will be diagnosed with polyps. between detection of m SEPT9 in blood plasma with presence of colorectal cancer. Comment on negative test result: a negative test result means that m SEPT9 methylation Comment on positive test result: a positive test result means that there is an increased like- could not be detected, so with this method, there is no indication for increased likelihood for the lihood for the presence of CRC. Individuals with positive test results are encouraged to undergo presence of CRC. Individuals with negative test results are correctly classified as being CRC a diagnostic colonoscopy. From 20 positive tests, an average of 1 person will be diagnosed with negative 99.7 % of the time. CRC and 7 will be diagnosed with polyps. Comment on negative test result: a negative test result means that m SEPT9 methylation could not be detected, so with this method, there is no indication for increased likelihood for the presence of CRC. Individuals with negative test results are correctly classified as being CRC negative 99.7 % of the time. TEST RESULT: POSITIVE An average of one out of two Epi pro Colon 2.0 CE positive patients suffer from colorectal cancer. The probability is 45 %. Figure 6: Example of a laboratory report LITERATURE 1. American Cancer Society, Colorectal Cancer Facts & Figures, Globocan 2008, Cancer Fact Sheet, Telephone survey Colorectal Cancer Alliance. CCA Denver, Zarca et al. Transversales Biarritz, Weiss G. and T. Rösch, European Oncology, Volume 6, Issue 1, Rösch et al. Poster Presentation at UEGW, Barcelona, Spain, Tetzner et al. UEGW, Allison et al. NEJM, Park et al. Am. J. Gastro., Tóth et al. UEGW, 2011.
8 INFORMATION FOR PHYSICIANS You can obtain further information on the Epi pro Colon 2.0 CE test at: Phone: contact@epigenomics.com Epigenomics AG Kleine Praesidentenstr Berlin Germany Not for sale in the United States. MKT0012GB, rev Epigenomics AG
Epi procolon The Blood Test for Colorectal Cancer Screening
Epi procolon The Blood Test for Colorectal Cancer Screening Epi procolon is an approved blood test for colorectal cancer screening. The US Preventive Services Task Force, the American Cancer Society and
More informationBlood-based SEPT9 Test in Colorectal Cancer Detection
Prof. JIANQIU SHENG, PENG JIN, YING HAN GI UNIT, BEIJING MILITARY GENERAL HOSPITAL Blood-based SEPT9 Test in Colorectal Cancer Detection A Report of Preliminary Study in China Disclosure of Interest: Nothing
More informationBlood based colon cancer screening in Europe. Methylated Septin 9: Biomarker of malignant development in the colon Measured in Tissue and Plasma
Blood based colon cancer screening in Europe Methylated Septin 9: Biomarker of malignant development in the colon Measured in Tissue and Plasma Molnár, Béla M.D., PhD 2nd Dept. of Medicine Semmelweis University
More informationEpigenomics AG Corporate Presentation
Epigenomics AG Corporate Presentation September 2013 www.epigenomics.com Safe Harbor Forward Looking Statements This communication contains certain forward-looking statements, including, without limitation,
More informationDetecting Cancer in Blood. Company presentation
Detecting Cancer in Blood Company presentation Safe harbor statement Forward Looking Statements This communication contains certain forward-looking statements, including, without limitation, statements
More informationColorectal Cancer: Preventable, Beatable, Treatable. American Cancer Society
Colorectal Cancer: Preventable, Beatable, Treatable American Cancer Society Reviewed January 2016 What we ll be talking about How common is colorectal cancer? What is colorectal cancer? What causes it?
More informationTable 40: Product Profile - MS9 Table 41: MS9 SWOT Analysis, 2013 Table 42: Septin-9 CRC Screening Marketed Laboratory-Developed Tests Table 43:
LIST OF TABLES 1.1 List of Tables Table 1: Initial Presenting Symptoms of Colorectal Cancer Table 2: Guideline Organization Recommendations for Non-Invasive Tests Table 3: TNM Classification System to
More informationColorectal Cancer: Preventable, Beatable, Treatable. American Cancer Society
Colorectal Cancer: Preventable, Beatable, Treatable American Cancer Society Reviewed January 2013 What we ll be talking about How common is colorectal cancer? What is colorectal cancer? What causes it?
More informationEpigenomics AG. May 2015. www.epigenomics.com
Epigenomics AG May 2015 www.epigenomics.com Safe Harbor Forward Looking Statements This communication contains certain forward-looking statements, including, without limitation, statements containing the
More informationEpigenomics AG. March 2015. www.epigenomics.com
Epigenomics AG March 2015 www.epigenomics.com Safe Harbor Forward Looking Statements This communication contains certain forward-looking statements, including, without limitation, statements containing
More informationReal-Time PCR Single-Day Test Protocol Flexible Workflow. Rx Only. Detecting Cancer In Blood.
Real-ime PCR Single-Day est Protocol Flexible Workflow Rx Only Intended Use, Contraindicarions, Warnings, Precautions & Limitations...2 What is Epi procolon...3 Detecting Methylated Septin 9 DN...4 HeavyMethyl
More informationcolon cancer Talk to your doctor about getting tested for colon cancer. They know how to prevent and you can, too. Take a look inside.
2006, American Cancer Society, Inc. No. 243900 Rev.01/08 The American Cancer Society is the nationwide community-based voluntary health organization dedicated to eliminating cancer as a major health problem
More informationCOLORECTAL CANCER SCREENING
COLORECTAL CANCER SCREENING By Douglas K. Rex, M.D., FACG & Suthat Liangpunsakul, M.D. Division of Gastroenterology and Hepatology, Department of Medicine Indiana University School of Medicine Indianapolis,
More informationMediPoint: In-Vitro Colorectal Cancer Screening Tests - Current and Future Players
Brochure More information from http://www.researchandmarkets.com/reports/2669701/ MediPoint: In-Vitro Colorectal Cancer Screening Tests - Current and Future Players Description: MediPoint: In-Vitro Colorectal
More informationColon Cancer. What Is Colon Cancer? What Are the Screening Methods?
Cancer of the colon or rectum (colorectal cancer) is the second most common cancer in the U.S. In fact, of all people born, 1 in 40 will die of the disease. What Is Colon Cancer? Colon cancer begins with
More informationFDA Executive Summary. Prepared for the March 26, 2014 meeting of the Molecular and Clinical Genetics Panel. P130001 Epi procolon Epigenomics AG
FDA Executive Summary Prepared for the March 26, 2014 meeting of the Molecular and Clinical Genetics Panel P130001 Epi procolon Epigenomics AG INTRODUCTION This document is the FDA Executive Summary for
More informationCancer Screening. Robert L. Robinson, MD, MS. Ambulatory Conference SIU School of Medicine Department of Internal Medicine.
Cancer Screening Robert L. Robinson, MD, MS Ambulatory Conference SIU School of Medicine Department of Internal Medicine March 13, 2003 Why screen for cancer? Early diagnosis often has a favorable prognosis
More informationBowel cancer: should I be screened?
Patient information from the BMJ Group Bowel cancer: should I be screened? Bowel cancer is a serious condition, but there are good treatments. Treatment works best if it's started early.to pick up early
More informationScreening for Cancer in Light of New Guidelines and Controversies. Christopher Celio, MD St. Jude Heritage Medical Group
Screening for Cancer in Light of New Guidelines and Controversies Christopher Celio, MD St. Jude Heritage Medical Group Screening Tests The 2 major objectives of a good screening program are: (1) detection
More informationAs Reported by the Senate Health, Human Services and Aging Committee. 127th General Assembly Regular Session Sub. S. B. No. 278 2007-2008 A B I L L
As Reported by the Senate Health, Human Services and Aging Committee 127th General Assembly Regular Session Sub. S. B. No. 278 2007-2008 Senator Coughlin Cosponsors: Senators Stivers, Mumper, Spada, Miller,
More informationCancer Expert Working Group on Cancer Prevention and Screening. Prevention and Screening for Colorectal Cancer
Cancer Expert Working Group on Cancer Prevention and Screening Prevention and Screening for Colorectal Cancer 1 What is colorectal cancer? Colorectum (colon and rectum, or the large bowel or large intestine)
More informationInequalities in Colon Cancer
Inequalities in Colon Cancer Chyke Doubeni, MD, FRCS, MPH Chair and The Presidential Associate Professor Department of Family Medicine and Community Health Perelman School of Medicine Senior Scholar, Center
More informationThank you very much for your interest in the Flu-FOBT Toolkit and Guide!
Thank you very much for your interest in the Flu-FOBT Toolkit and Guide! The Colorado Colorectal Screening Program s (The Program) Flu-FOBT initiative assists community health clinics with increasing colorectal
More informationThe Forzani MacPhail Colon Cancer Screening Centre Frequently Asked Questions. What is the Forzani MacPhail Colon Cancer Screening Centre?
The Forzani MacPhail Colon Cancer Screening Centre Frequently Asked Questions What is the Forzani MacPhail Colon Cancer Screening Centre? The Forzani and MacPhail Colon Cancer Screening Centre (CCSC) is
More informationCancer screening: cost-effectiveness. Endoscopic polypectomy: : CRC mortality. Endoscopic polypectomy: : CRC incidence
Cribado del cáncer (colorrectal): las pruebas de detección precoz salvan vidas Dr. Antoni Castells Servicio de Gastroenterología Hospital Clínic nic,, Barcelona (castells@clinic.cat) Conditions for a population-based
More informationColorado Cancer Coalition Priorities: 2016 2018
Option 3 of 10: Screening & Early Detection: Screening Rates Presenter: Toni Panetta, MA, Director of Mission Programs, Susan G. Komen Colorado Goal 5: Objective 5.1: Objective 5.2 Focus Area: Focus Area:
More informationFor Yourself and Loved Ones. A Colorectal Cancer Kit from NFCR
For Yourself and Loved Ones A Colorectal Cancer Kit from NFCR ABOUT THE NFCR COLORECTAL CANCER PREVENTION AND DETECTION KIT Colorectal cancer, also called colon cancer or large bowel cancer, includes cancerous
More informationTest Your Breast Cancer Knowledge
Test Your Breast Cancer Knowledge Regular exams and a good understanding can help defend against breast cancer, yet many women hold outdated ideas about their own breast cancer risk. Take this quiz to
More informationParticipate in Cancer Screening
Key #3 Participate in Cancer Screening What is Cancer? The National Cancer Institute defines cancer as A term for diseases in which abnormal cells divide without control and can invade nearby tissues.
More informationColorectal Cancer Screening Behaviors among American Indians in the Midwest
JOURNAL OF HD RP Journal of Health Disparities Research and Practice Volume 4, Number 2, Fall 2010, pp. 35 40 2010 Center for Health Disparities Research School of Community Health Sciences University
More informationPrevention Checklist for Men
Page 1 of 5 Prevention Checklist for Men Great progress has been made in cancer research, but we still don t understand exactly what causes most cancers. We do know that many factors put us at higher risk
More informationCancer Facts for Women
2006, American Cancer Society, Inc. No.200700-Rev.03/08 The American Cancer Society is the nationwide community-based voluntary health organization dedicated to eliminating cancer as a major health problem
More informationCANCER FACTS. for the Asian American Community ASIAN AMERICAN HEALTH INITIATIVE. Department of Health and Human Services Montgomery County
CANCER FACTS for the Asian American Community ASIAN AMERICAN HEALTH INITIATIVE Department of Health and Human Services Montgomery County ABOUT THE ASIAN AMERICAN HEALTH INITIATIVE ASIAN AMERICAN HEALTH
More informationThis publication was developed and produced with funding from the Centers for Disease Control and Prevention under a cooperative agreement.
This publication was developed and produced with funding from the Centers for Disease Control and Prevention under a cooperative agreement. Suggested Citation Centers for Disease Control and Prevention.
More informationNuevas tecnologías basadas en biomarcadores para oncología
Nuevas tecnologías basadas en biomarcadores para oncología Simposio ASEBIO 14 de marzo 2013, PCB Jose Jimeno, MD, PhD Co-Founder / Vice Chairman Pangaea Biotech SL Barcelona, Spain PANGAEA BIOTECH BUSINESS
More informationCXCA-MSP. The next step in cervical cancer prevention! GynTect : Epigenetic biomarkers for reliable cancer diagnostics. www.gbo.
CXCA-MSP The next step in cervical cancer prevention! GynTect : Epigenetic biomarkers for reliable cancer diagnostics www.gbo.com/diagnostics H 3 C NH 2 NH H 3 C 2 N mc N mc N H N O H O The challenge of
More informationExamples of good screening tests include: mammography for breast cancer screening and Pap smears for cervical cancer screening.
CANCER SCREENING Dr. Tracy Sexton (updated July 2010) What is screening? Screening is the identification of asymptomatic disease or risk factors by history taking, physical examination, laboratory tests
More informationStudy of Proposed Mandatory Health Insurance Coverage for Colorectal Cancer Screening
Study of Proposed Mandatory Health Insurance Coverage for Colorectal Cancer Screening A Report to the Governor and the Legislature of the State of Hawai i Report No. 10-02 February 2010 THE AUDITOR STATE
More informationCOMMUNITY REPORT March 2013 WJMC.ORG
March Is Colon Cancer Awareness Month 10 Best Ways To Prevent Colon Cancer Talk by Steve Venturatos, MD Sign Up to Get Screened Blood Pressure Interactive Colon Exhibit Light Refreshments Door Prizes*
More informationColorectal Cancer Screening (FOBT)
Colorectal Cancer Screening (FOBT) Rates of colorectal cancer screening are slowly increasing but remain very low in Ontario. In response, Cancer Care Ontario and the Ministry of Health and Long-Term Care
More informationAn Action Guide for Engaging Employers and Professional Medical Organizations
Increasing Quality Colorectal Cancer Screening and Promoting Screen Quality: An Action Guide for Engaging Employers and Professional Medical Organizations U.S. Department of Health and Human Services,
More informationIncrease Hepatitis C Virus Screening and Treatment
18 Increase Hepatitis C Virus Screening and Treatment Situation The number of deaths from liver cancer in Japan has been rising rapidly since 1975, and now stands at more than 30,000 per year. About 80
More informationClinical Indicator Ages 19-29 Ages 30-39 Ages 40-49 Ages 50-64 Ages 65+ Frequency of visit as recommended by PCP
SCREENING EXAMINATION & COUNSELING UPMC Health Plan Clinical Indicator Ages 19-29 Ages 30-39 Ages 40-49 Ages 50-64 Ages 65+ Annually Physical Exam and Counseling 1 Blood Pressure 2 At each visit. At least
More informationBackground Information
Background Information r One About NAT Testing NAT testing has been widely embraced by laboratories throughout the world as a means to identify CT cases because of its high degree of accuracy and reliability
More informationHow common is bowel cancer?
information Primary Care Society for Gastroenterology Bowel Cancer (1 of 6) How common is bowel cancer? Each year 35,000 people in Britain are diagnosed with cancer of the bowel, that is to say cancer
More informationScreening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008
Dr. B. Levin is Professor Emeritus, The University of Texas MD Anderson Cancer Center, Houston, TX. Dr. Lieberman is Chief, Division of Gastroenterology, Oregon Health and Science University, Portland
More information25-hydroxyvitamin D: from bone and mineral to general health marker
DIABETES 25 OH Vitamin D TOTAL Assay 25-hydroxyvitamin D: from bone and mineral to general health marker FOR OUTSIDE THE US AND CANADA ONLY Vitamin D Receptors Brain Heart Breast Colon Pancreas Prostate
More information4/30/2013 HPV VACCINE AND NORTH DAKOTA HPV IMMUNIZATION RATES HUMAN PAPILLOMAVIRUS (HPV) HUMAN PAPILLOMAVIRUS HPV CONTINUED
HPV VACCINE AND NORTH DAKOTA HPV IMMUNIZATION RATES HUMAN PAPILLOMAVIRUS (HPV) HUMAN PAPILLOMAVIRUS What is human papillomavirus (HPV)? HPV is the most common sexually transmitted infection. There are
More informationPARTNERS IN HEALTH AT WORK
PARTNERS IN HEALTH AT WORK Editors: Damir Mazlagic, M.D., M.P.H., Medical Director; Patricia Haner, Practice Manager Contact: Berkshire Occupational health, 165 Tor Court, Pittsfield, MA 01240; Telephone:
More informationColorectal cancer. A guide for journalists on colorectal cancer and its treatment
Colorectal cancer A guide for journalists on colorectal cancer and its treatment Contents Contents 2 3 Section 1: Colorectal cancer 4 i. What is colorectal cancer? 4 ii. Causes and risk factors 4 iii.
More informationSafe Harbor Statement Writing - Cologuard Cancer
Third-Quarter 2015 Earnings Call October 29, 2015 Safe Harbor statement Certain statements made in this presentation contain forward-looking statements within the meaning of Section 27A of the Securities
More informationProgress and Prospects in Ovarian Cancer Screening and Prevention
Progress and Prospects in Ovarian Cancer Screening and Prevention Rebecca Stone, MD MS Assistant Professor Kelly Gynecologic Oncology Service The Johns Hopkins Hospital 1 No Disclosures 4/12/2016 2 Ovarian
More informationTO THE SENATE COMMITTEES ON. COMMERCE AND CONSUMER PROTECTION AND HEALTH. TWENTY-FIFTH LEGISLATURE Regular Session of 2010
II CPN HTH LINDA LINGLE GOVERNOR JAMES R. AIONA. JR. LT. GOVERNOR STATE OF HAWAII OFFICE OF THE DIRECTOR DEPARTMENT OF COMMERCE AND CONSUMER AFFAIRS 335 MERCHANT STREET, ROOM 310 P.O. Box 541 HONOLULU,
More informationIntroduction to Pathology and Diagnostic Medicine
Harvard-MIT Division of Health Sciences and Technology HST.035: Principle and Practice of Human Pathology Dr. Badizadegan Introduction to Pathology and Diagnostic Medicine Spring 2003 What is pathology?
More informationOneStep Fecal Occult Blood RapiDip InstaTest. Cat # 13020-1
CORTEZ DIAGNOSTICS, INC. 23961 Craftsman Road, Suite D/E/F, Calabasas, CA 91302 USA Tel: (818) 591-3030 Fax: (818) 591-8383 E-mail: onestep@rapidtest.com Web site: www.rapidtest.com See external label
More informationPreventive services process, Practice Solutions. Generating reminder letters with MD verification
Preventive services process, Practice Solutions. Generating reminder letters with MD verification By: Michelle Greiver MD CCFP Prepared for: North York Family Health Team, Summer 2012 Funding: Cancer Care
More informationHealth Policy Advisory Committee on Technology
Health Policy Advisory Committee on Technology Technology Overview Blood and stool biomarker testing for colorectal cancer screening July 2015 State of Queensland (Queensland Department of Health) 2015
More informationPSA Testing 101. Stanley H. Weiss, MD. Professor, UMDNJ-New Jersey Medical School. Director & PI, Essex County Cancer Coalition. weiss@umdnj.
PSA Testing 101 Stanley H. Weiss, MD Professor, UMDNJ-New Jersey Medical School Director & PI, Essex County Cancer Coalition weiss@umdnj.edu September 23, 2010 Screening: 3 tests for PCa A good screening
More informationCancer Screening 22M 36% 56% Only 56% of uninsured women aged 50 74 are up-to-date with mammography screening. Colorectal Cancer Breast Cancer
July 2010 22M 22 million adults aged 50 75 need to be screened for colorectal cancer, and 7 million women aged 50 74 need to be screened for breast cancer. Cancer Screening Colorectal Cancer Breast Cancer
More informationColorectal Cancer Care A Cancer Care Map for Patients
Colorectal Cancer Care A Cancer Care Map for Patients Understanding the process of care that a patient goes through in the diagnosis and treatment of colorectal cancer in BC. Colorectal Cancer Care Map
More informationBiomarkers for early detection of asbestosassociated
Biomarkers for early detection of asbestosassociated cancers ( study) G. Johnen, B. Pesch, D. Weber, K. Gawrych, S. Casjens, I. Raiko, O. Bryk, D. Taeger, S. Meier, P. Rozynek, T. Wiethege, G. Aguilar-Madrid,
More informationSCREENING FOR THE BIG THREE CANCERS: BREAST, CERVICAL and COLORECTAL. See your doctor for screening advice
SCREENING FOR THE BIG THREE CANCERS: BREAST, CERVICAL and COLORECTAL See your doctor for screening advice SCREENING FOR THE BIG THREE CANCERS: BREAST, CERVICAL and COLORECTAL Cancer is a serious, dreaded
More informationPROSTATE CANCER SCREENING PROSTATE CANCER SCREENING
3:45 4:45pm Screening Guidelines for Men's Health SPEAKER Radha Rao, MD Presenter Disclosure Information The following relationships exist related to this presentation: Radha Rao, MD: No financial relationships
More informationClinical Trials: Questions and Answers
Clinical Trials: Questions and Answers Key Points Clinical trials are research studies that test how well new medical approaches work in people (see Question 1). Every clinical trial has a protocol, which
More informationTogether, The Strength
DECATUR County Indiana Together, The Strength to Fight Cancer Barbara Taylor, MD Cancer Committee Chairperson Rahul Dewan, DO Radiation Oncology Cancer Liasion Jaime Ayon, MD Medical Oncology/ Hematology
More informationThis letter can be copied and pasted in a word document for use with your letterhead.
This letter can be copied and pasted in a word document for use with your letterhead. Date Name Street City Dear (Name): Our office has made a commitment to promote the health of its members, and to provide
More informationCancer Data for South Florida: A Tool for Identifying Communities in Need
Cancer Data for South Florida: A Tool for Identifying Communities in Need Report to the Health Foundation of South Florida Supported by an Administrative Grant to the University of Miami Sylvester Comprehensive
More informationALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)
ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in
More informationCancer Screening and Early Detection Guidelines
Cancer Screening and Early Detection Guidelines Guillermo Tortolero Luna, MD, PhD Director Cancer Control and Population Sciences Program University of Puerto Rico Comprehensive Cancer Center ASPPR Clinical
More informationPatient Cost Sharing and Colonoscopy Cancer Screening Use in the Military Health System
Patient Cost Sharing and Colonoscopy Cancer Screening Use in the Military Health System Prepared by Arnie Brooks Kennell and Associates Prepared For TRICARE Management Activity Importance of Colorectal
More informationPSA Testing for Prostate Cancer An information sheet for men considering a PSA Test
PSA Testing for Prostate Cancer An information sheet for men considering a PSA Test What is the aim of this leaflet? Prostate cancer is a serious condition. The PSA test, which can give an early indication
More informationPSA Screening for Prostate Cancer Information for Care Providers
All men should know they are having a PSA test and be informed of the implications prior to testing. This booklet was created to help primary care providers offer men information about the risks and benefits
More informationClinical Trials and Screening: What You Need to Know
Scan for mobile link. Clinical Trials and Screening: What You Need to Know What is a Clinical Trial? At A Glance A clinical trial is a research study that tests how well new medical techniques work in
More informationIndividualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing
Individualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing These Are Hopeful Times for Lung Cancer Survivors When people first learn they have cancer, they are often afraid. But
More informationEpigenomics AG. 00:00 Operator
Epigenomics AG 00:00 Operator Good afternoon, ladies and gentlemen. I would like to welcome you to Epigenomics conference call regarding the nine-month financial result 2015. At this time all participants
More informationFrequently Asked Questions About Ovarian Cancer
Media Contact: Gerri Gomez Howard Cell: 303-748-3933 gerri@gomezhowardgroup.com Frequently Asked Questions About Ovarian Cancer What is ovarian cancer? Ovarian cancer is a cancer that forms in tissues
More informationColon Polyps. What I need to know about. National Digestive Diseases Information Clearinghouse NATIONAL INSTITUTES OF HEALTH
What I need to know about Colon Polyps U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH National Digestive Diseases Information Clearinghouse What I need to know about Colon
More informationla lotta al cancro non ha colore Screening Let s play ahead against tumors
la lotta al cancro non ha colore la lotta al cancro non ha colore Screening Let s play ahead against tumors Why this booklet? The word cancer screening indicates the tests for the early detection of cancer.
More informationinflammation of the pancreas and damage to the an increased risk of hypertension, stroke and Table 7.1: Classification of alcohol consumption
H E A LT H SURVEY Alcohol Consumption 7 Alcohol Consumption N AT I O N A L Introduction Excessive alcohol consumption is associated with inflammation of the pancreas and damage to the an increased risk
More informationHow To Know If You Are At Risk For Cancer
Ana Maria Lopez, MD, MPH, FACP Professor of Medicine and Pathology Arizona Cancer Center University of Arizona Definitions Rationale Who is at risk Guidelines Breast Cancer Colorectal Cancer Prostate Cancer
More informationThe recommendations made throughout this book are by the National Health and Medical Research Council (NHMRC).
INTRODUCTION This book has been prepared for people with bowel cancer, their families and friends. The first section is for people with bowel cancer, and is intended to help you understand what bowel cancer
More informationCMS Denies Medicare Reimbursement Eligibility for Virtual Colonoscopies
CMS Denies Medicare Reimbursement Eligibility for Virtual Colonoscopies By Craig A. Conway, J.D., LL.M. The Centers for Medicare and Medicaid Services (CMS) recently issued a memorandum stating that it
More informationTheories on Metastasis: Innovative Thinking An Advocacy Perspective
Theories on Metastasis: Innovative Thinking An Advocacy Perspective Project LEAD Workshop NBCC Annual Advocacy Conference 2011 Musa Mayer AdvancedBC.org 1 The Big Question If we want to end death from
More informationLaparoscopic Surgery of the Colon and Rectum (Large Intestine) A Simple Guide to Help Answer Your Questions
Laparoscopic Surgery of the Colon and Rectum (Large Intestine) A Simple Guide to Help Answer Your Questions What are the Colon and Rectum? The colon and rectum together make up the large intestine. After
More informationLucia Migliore. Transfer of recent evidences concerning genetic and epigenetic risk factors of complex diseases on clinical practice
Lucia Migliore Transfer of recent evidences concerning genetic and epigenetic risk factors of complex diseases on clinical practice Dipartimento di Ricerca Traslazionale e Nuove Tecnologie in Medicina
More informationCraig Hallum Conference Investor Presentation
Craig Hallum Conference Investor Presentation Improving cancer outcomes with groundbreaking precision in molecular testing Paul Kinnon President and CEO Sept 2015 1 Forward-Looking Statements Certain statements
More informationA guide for the patient
Understanding series LUNG CANCER CLINICAL TRIALS 1-800-298-2436 LungCancerAlliance.org A guide for the patient TABLE OF CONTENTS The Basics What is a Clinical Trial?...3 Types of Clinical Trials... 3 Phases
More informationCancer in North Carolina 2013 Report
Cancer in North Carolina 2013 Report January 2014 Updated by Central Cancer Registry Cancer in North Carolina Purpose Cancer is the leading cause of death in North Carolina even though cancer mortality
More informationColorectal Cancer Facts and Figures In support of the SPECTAcolor Biobank Project
Colorectal Cancer Facts and Figures In support of the SPECTAcolor Biobank Project ITALY Contact: Mathilde Fenoulhet, Fundraising Project Coordinator EORTC Headquarters mathilde.fenoulhet@eortc.be +32 2
More informationThe Hereditary Colorectal Cancer Website has been sponsored by the Robert Rauschenberg Foundation
Introduction The Hereditary Colorectal Cancer Website has been sponsored by the Robert Rauschenberg Foundation Hereditary nonpolyposis colorectal cancer (HNPCC) syndrome was first described over 100 years
More informationUnderstanding CA 125 Levels A GUIDE FOR OVARIAN CANCER PATIENTS. foundationforwomenscancer.org
Understanding CA 125 Levels A GUIDE FOR OVARIAN CANCER PATIENTS foundationforwomenscancer.org Contents Introduction...1 CA 125................................... 1 The CA 125 Test...2 The Use of the CA
More informationco-sponsored by the Health & Physical Education Department, the Health Services Office, and the Student Development Center
Cancer is a group of more than 100 related diseases. Normally, cells grow and divide to produce more cells to keep the body healthy. Sometimes, this process goes wrong. New cells form when the body doesn
More informationClinic Readiness Survey Leadership
Clinic Readiness Survey Leadership Date of interview: Organizational interview ID#: Interviewer: Interview modality: 1 phone 2 in-person STOP CRC is a program about colon health. As part of STOP CRC, we
More informationOntario Health Insurance Plan (OHIP) Billing Codes Information and Procedures for Claiming the Cumulative Preventative Care Bonus
Ontario Health Insurance Plan (OHIP) Billing Codes Information and Procedures for Claiming the Cumulative Preventative Care Bonus Eligible Patient Enrolment Model (PEM) physicians may receive Cumulative
More informationC-CoP (1B1b) Results, Procedure-Based Report for Colorectal Cancer Screening by Jurisdiction
Appendix J: Explanation of Colorectal Cancer Reports C-CoP (1B1b) Results, Procedure-Based Report for Colorectal Cancer Screening by Jurisdiction Purpose: The purpose of this report is to give a summary
More informationCancer Screening in the United States, 2009: A Review of Current American Cancer Society Guidelines and Issues in Cancer Screening
Cancer Screening in the United States, 2009: A Review of Current American Cancer Society Guidelines and Issues in Cancer Screening Robert A. Smith, PhD 1, Vilma Cokkinides, PhD 2, Otis W. Brawley, MD 3
More informationPCA3 DETECTION TEST FOR PROSTATE CANCER DO YOU KNOW YOUR RISK OF HAVING CANCER?
PCA3 DETECTION TEST FOR PROSTATE CANCER DO YOU KNOW YOUR RISK OF HAVING CANCER? PCA3 DETECTION TEST FOR PROSTATE CANCER There is a range of methods available to your healthcare professional to verify the
More informationD. Risk Status: All patients who are at average risk, increased risk, or in need of surveillance are eligible for direct screening services.
ANTHC CRCCP Policy No. 001 Page 1 of 3 ANTHC CRCCP ELIGIBILITY Purpose: To establish and define the ANTHC CRCCP eligibility criteria for direct screening services. Eligibility will be determined by patient
More informationButler Memorial Hospital Community Health Needs Assessment 2013
Butler Memorial Hospital Community Health Needs Assessment 2013 Butler County best represents the community that Butler Memorial Hospital serves. Butler Memorial Hospital (BMH) has conducted community
More informationCancer screening: indications, benefits and myths
Cancer screening: indications, benefits and myths Silvia Deandrea Institute for Health and Consumer Protection Public Health Policy Support Unit Healthcare Quality Team Joint Research Centre The European
More information